Novel Trial for the Treatment of Steroid Dependency in Minimal Change Disease: Combined Therapy of Camostat Mesilate and Glycyrrhizin

Publisher： Karger

E-ISSN： 2235-3186|90|3|357-360

ISSN： 1660-8151

Source： Nephron, Vol.90, Iss.3, 2002-02, pp. : 357-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Successful Treatment of Steroid-Resistant Minimal Change Disease with Mycophenolate Mofetil

By  

American Journal of Nephrology, Vol. 22, Iss. 5-6, 2002-10 ,pp. : 569-572

Karger

Access to resources Recommend Favorite

The Serine Protease Inhibitor Camostat Mesilate Attenuates the Progression of Chronic Kidney Disease through its Antioxidant Effects

By  

Nephron, Vol. 129, Iss. 3, 2015-03 ,pp. : 223-232

Karger

Access to resources Recommend Favorite

Simultaneous Improvement of Minimal-Change Nephrotic Syndrome and Anemia with Steroid Therapy

By  

Nephron, Vol. 81, Iss. 1, 1999-01 ,pp. : 84-88

Karger

Access to resources Recommend Favorite

Blood Pressure in Children with Minimal Change Nephrotic Syndrome during Oedema and after Steroid Therapy: The Influence of Familial Essential Hypertension

By  

Kidney and Blood Pressure Research, Vol. 32, Iss. 4, 2009-09 ,pp. : 258-262

Karger

Access to resources Recommend Favorite

Urinary Soluble HLA Class I Antigen in Patients with Minimal Change Disease: A Predictor of Steroid Response

By  

Nephron, Vol. 79, Iss. 1, 1998-04 ,pp. : 44-49

Karger

Access to resources Recommend Favorite